---
schema_version: "secwatch.filing_event.v1"
accession: "0001728117-22-000018"
form_type: "8-K"
ticker: "GOSS"
cik: "0001728117"
company_name: "Gossamer Bio, Inc."
filed_at: "2022-03-03T23:59:59+00:00"
generated_at: "2026-06-27T02:03:56.694642+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Gossamer Bio reports FY2021 net loss of $234M; cash $325M; pipeline milestones set for 2022

## Summary
- Net loss for Q4 2021 was $56.3M ($0.74/share); FY2021 net loss $234M ($3.13/share).
- Cash, cash equivalents and marketable securities totaled $325.2M at year-end 2021; expected to fund into H2 2023.
- GB004 Phase 2 SHIFT-UC topline data (mild-to-moderate UC) expected Q2 2022; treat-through week 36 data in Q4 2022.
- Seralutinib (GB002) Phase 2 TORREY PAH study topline data expected H2 2022, subject to COVID-19 developments.
- GB5121 IND active; global Phase 1b/2 trial for primary CNS lymphoma expected to initiate in H1 2022.

## SEC filing metadata
- accession: 0001728117-22-000018
- form_type: 8-K
- ticker: GOSS
- cik: 0001728117
- company_name: Gossamer Bio, Inc.
- filed_at: 2022-03-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728117/000172811722000018/0001728117-22-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728117/000172811722000018/goss-20220303.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001728117-22-000018
- JSON: https://secwatch.observer/filing/0001728117-22-000018.json
- Plain text: https://secwatch.observer/filing/0001728117-22-000018.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.